Eligible for initial tests

**Subclinical Trial**
- VMT: neg
- MFT: neg
- WDT/NCS: pos
- Reaction of skin only (RR or ENL)

- **Eligible for initial tests**
- **Excluded, but steroids**
- **Prednisolone (20 weeks)**
- **Repeat tests (20 weeks, 12 and 18 months)**
- **VMT/MFT monthly**

Primary outcome:
1. Proportion of patients developing clinical NFI as defined by MFT/VMT change

Secondary outcomes - detected by NCS and/or WDT:
2. Proportion of patients with fully recovered subclinical function (all nerves)
3. Proportion of patients with improved, unchanged or deteriorated subclinical functions (based on count of impaired functions)
4. Proportion of patients with recovered, improved, unchanged or deteriorated subclinical functions of a given nerve
5. Spontaneous recovery of subclinical function (placebo group)
6. Proportion of improved, unchanged or deteriorated subclinical functions (placebo group)
7. Proportion of patients with serious adverse events or other complications leaving the trial - incl. skin reactions and ENL

Primary outcome:
1. Proportion of patients with restored or improved nerve function as measured by MFT/VMT (all nerves)

Secondary outcomes (detected by MFT/VMT):
2. Proportion of patients with 'recovered', improved, 'unchanged' or deteriorated function of a given nerve (e.g. ulnar nerve)
3. Proportion with improved Count of Nerve Function Impairments (CNFI)
4. Proportion of patients with improved Reaction Severity Scale
5. Proportion of patients with serious adverse events or other complications leaving the trial
6. Proportion of patients with improved SALSA and P-scale scores